Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Suboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to reach glycemic targets. Basic research in diabetes is endeavoring to identify new actives working as insulin savers, use of which could delay the introduction of injectable insulin or reduce the insulin dose needed. Commonly available as a nutraceutical, berberine is a potential candidate. METHODS AND RESULTS: Because its low oral bioavailability can be overcome by P-glycoprotein inhibitors like herbal polyphenols, we have tested the nutraceutical combination of Berberis aristata extract and Silybum marianum extract (Berberol(®)) in type 2 diabetes in terms of its additive effect when combined with a conventional oral regimen for patients with suboptimal glycemic control. After 90 days of treatment, the nutraceutical association had a positive effect on glycemic and lipid parameters, significantly reducing glycosylated hemoglobin, basal insulin, homeostatic model assessment of insulin resistance, total and low-density lipoprotein cholesterol, and triglycerides. A relevant effect was also observed in terms of liver function by measuring aspartate transaminase and alanine transaminase. The product had a good safety profile, with distinctive gastrointestinal side effects likely due to its acarbose-like action. CONCLUSION: Although further studies should be carried out to confirm our data, Berberol could be considered a good candidate as an adjunctive treatment option in diabetes, especially in patients with suboptimal glycemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Chen, W., Miao, Y.-Q., Fan, D.-J., Yang, S.-S., Lin, X., Meng, L.-K., & Tang, X. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9632-z · Cited by 363 · cited 1×
“However, despite these functions, berberine has poor oral bioavailability.(17) In humans, this appears to be due to a P-glycoprotein-mediated gut extrusion process(18) and substantial excretion in bile.”
The involvement of P-glycoprotein in berberine absorption
Pan, G., Wang, G., Liu, X., Fawcett, J. P., & Xie, Y. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.t01-1-910403.x · Cited by 225
Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products: Buyer Beware!
Gordon, R. Y., Cooperman, T., Obermeyer, W., & Becker, D. J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.382 · Cited by 184 · cited 1×
“11 However, these products do not take into consideration the poor standardization of the raw materials 12 and the risk to consumers due to the possible presence of mycotoxic contaminants like citrinin.”
Cited by
Current knowledge and pharmacological profile of berberine: An update
Kumar, A., Ekavali, Chopra, K., Mukherjee, M., Pottabathini, R., & Dhull, D. K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.068 · Cited by 530
The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
Research progress on berberine with a special focus on its oral bioavailability
Liu, C.-S., Zheng, Y.-R., Zhang, Y.-F., & Long, X.-Y. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.02.001 · Cited by 363
Pirillo, A., & Catapano, A. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.032 · Cited by 305
Oxenkrug, G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8497-4 · Cited by 254
Fogacci, F., Grassi, D., Rizzo, M., & Cicero, A. F. G. (2019) · Phytotherapy Research · doi:10.1002/ptr.6282 · Cited by 61
Di Pierro, F., Bellone, I., Rapacioli, G., & Putignano, P. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s78877 · Cited by 48
Solnier, J., Zhang, Y., Kuo, Y., Du, M., Roh, K., Gahler, R., Wood, S., & Chang, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112567 · Cited by 47
Polycystic ovary syndrome management: a review of the possible amazing role of berberine
Rondanelli, M., Infantino, V., Riva, A., Petrangolini, G., Faliva, M. A., Peroni, G., Naso, M., Nichetti, M., Spadaccini, D., Gasparri, C., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05450-4 · Cited by 46
Rashidi, H., Namjoyan, F., Mehraban, Z., Zakerkish, M., Ghaderian, S. B., & Latifi, S. M. (2018) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp.64180 · Cited by 28
Metadata
- Authors
- Di Pierro Francesco, F., Villanova, Agostini, F., Soverini, V., Marchesini, G., & Marzocchi
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 5
- Pages
- 213
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W2068708312
- Cited by
- 86
- References
- 4
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.